A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to compare the efficacy and safety of higher doses of
rituximab to a combination of standard doses of Rituxan + CVP (Cyclophosphamide, Vincristine,
and Prednisone) in patients with chronic Idiopathic Thrombocytopenic Purpura (ITP who did not
respond to or relapsed after standard doses of rituximab.